Published on
February 4, 2025
- 13:00 GMT
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting ...
Lead asset EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. Northstrive Biosciences Inc. is preparing the necessary …
Distribution channels:
Consumer Goods
...
